Zealand Pharma’s drug reduces weight by 8.6% in early-stage study, ET HealthWorld

[Pelican Press 0]

Zealand Pharma’s ***** reduces weight by 8.6% in early-stage study, ET HealthWorld

London: Zealand Pharma said on Thursday an early-stage study showed a high dose of its ***** helped reduce weight by an average 8.6 per cent after 16 weekly doses.

The company said the data paves the way for testing the *****, petrelintide, in a mid-stage trial for weight loss, which it expects to start later this year.

The weight loss achieved with the high dose of the ***** was much higher than the 1.7 per cent reduction with a placebo in one part of the trial that involved 48 participants. Another part of the early-stage study was testing the ***** in 20 people with lower doses.

Petrelintide belongs to a class of drugs known as the long-acting amylin analog, which mimics a hormone called amylin that is co-secreted with insulin in response to ingested nutrients.

The Danish company is also working with ******* drugmaker Boehringer Ingelheim to test another ***** survodutide, which belongs to the same class of GLP-1 agonists as Eli Lilly’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy.

(Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)

• Published On Jun 21, 2024 at 05:56 AM IST

This is the hidden content, please

• Sign In
• or
• Sign Up

weight loss *****, Health News, Zealand Pharma, *****, petrelintide, early-stage study, high dose, reduce weight
#Zealand #Pharmas #***** #reduces #weight #earlystage #study #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up